> Detailanzeige
Bayat, S.;
Simon, D.;
Pecherstorfer, C.;
Ellmann, H.;
Figueiredo, C.;
Englbrecht, M.;
Hueber, A.;
Kleyer, A.;
Rech, J.;
Schett, G.
SAT0556 FINE STRUCTURE ANALYSIS OF THE INTER-RELATION BETWEEN TOPHUS DEPOSITION AND BONE LESIONS IN GOUT USING A COMBINATION OF DUAL ENERGY AND HIGH-RESOLUTION CT
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: SAT0556 FINE STRUCTURE ANALYSIS OF THE INTER-RELATION BETWEEN TOPHUS DEPOSITION AND BONE LESIONS IN GOUT USING A COMBINATION OF DUAL ENERGY AND HIGH-RESOLUTION CT
- Beteiligte: Bayat, S.; Simon, D.; Pecherstorfer, C.; Ellmann, H.; Figueiredo, C.; Englbrecht, M.; Hueber, A.; Kleyer, A.; Rech, J.; Schett, G.
-
Erschienen:
BMJ, 2020
- Erschienen in: Annals of the Rheumatic Diseases, 79 (2020) Suppl 1, Seite 1236.1-1236
- Sprache: Englisch
- DOI: 10.1136/annrheumdis-2020-eular.2151
- ISSN: 0003-4967; 1468-2060
- Schlagwörter: General Biochemistry, Genetics and Molecular Biology ; Immunology ; Immunology and Allergy ; Rheumatology
- Entstehung:
- Anmerkungen:
- Beschreibung: <jats:sec><jats:title>Background:</jats:title><jats:p>Deposition of uric acid crystals cause an inflammatory reaction, which can lead to structural bone changes, if such deposits form adjacent to cortical bone [1, 2]. Both erosions and bony spurs can form in conjunction with tophus deposition. The exact spatial inter-relation between tophi and structural bone lesions in humans in vivo is not fully characterized.</jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p>To spatially relate structural bone changes (erosions, osteophytes) to the deposition of monosodium urate crystals in the first metatarsophalangeal (MTP1) joint in patients with tophaceous gout.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>Tophaceous gout patients with clinically detected tophi at the MTP1 joint underwent simultaneous dual energy computed tomography (DECT) and high-resolution peripheral quantitative computed tomography (HR-pQCT) of the feet. Tophi detected by DECT and erosions and osteophytes detected by HR-pQCT were overlayed to define their exact anatomical relation. Furthermore, feet of sex- and age-matched healthy controls (HC) were scanned to define the normal architecture of the MTP1 joint.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>Gout patients (N=20) had significantly higher numbers (5 (0–17 vs. 1 (1– 2)) and volumes (45.32 mm<jats:sup>3</jats:sup>(7.26–550.32) vs. 0.82 mm<jats:sup>3</jats:sup>(0.15–21.8)) of bone erosions as well as significantly higher numbers (10.5 (0-26) vs. 1 (0-10)) and sizes of osteophytes (4.93 mm (0.77-7.19 mm vs. 0.93 mm (0.05-7.61 mm)<jats:sup>)</jats:sup>than healthy controls (N=20). Erosions were in direct spatial relation to bone erosions, while osteophytic responses were more widespread and affected bone regions on the MTP1, which were not directly adjacent to tophi. Median tophus volume detected by DECT (0.12 mm<jats:sup>3</jats:sup>(0.01–2.53)) was associated with the total volume of erosions (r=0.597, p=0.005).</jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p>This study demonstrates that bone changes in gout are substantial and not only include erosions but also widespread architectural bone remodeling associated osteophyte formation. While there is a direct spatial relation between tophi and bone erosions the anabolic bone responses in gout are more widespread.</jats:p></jats:sec><jats:sec><jats:title>References:</jats:title><jats:p>[1]Dalbeth, N. et al. Ann Rheum Dis. 2015 Jun;74(6):1030-6.</jats:p><jats:p>[2]Dalbeth, N. et al. Arthritis Res Ther. 2012; 14(4): R165.</jats:p><jats:fig position="float" orientation="portrait"><jats:graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EUROAB-2020-SAT-6-SAT0556_IF0001" position="float" orientation="portrait" /></jats:fig><jats:p>Data are based on high-resolution peripheral quantitative computed tomography (HR-pQCT) of metatarsophalangeal joints I in gout patients (grey boxplots) and healthy controls (white boxplots). (A) number of bone erosions, (B) volume of bone erosions, (C) number of osteophytes and (D) size of osteophytes. Data are shown as medians and inter-quartile ranges (boxes).</jats:p><jats:fig position="float" orientation="portrait"><jats:graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EUROAB-2020-SAT-6-SAT0556_IF0002" position="float" orientation="portrait" /></jats:fig><jats:p>Distribution of (A) tophi based on dual-energy computed tomography (DECT) as well as (B) bone erosions and (C) osteophytes based on high-resolution peripheral quantitative computed tomography (HR-pQCT) of metatarsophalangeal (MTP) I head in gout patients. Data are shown for the different regions of the MTPI head including the plantar, medial, dorsal and lateral region of the metatarsal head, as well as the medial and lateral sesamoid bones. Data indicate percentage of patients with tophi, erosions and osteophytes in respective region.</jats:p></jats:sec><jats:sec><jats:title>Disclosure of Interests:</jats:title><jats:p>Sara Bayat Speakers bureau: Novartis, David Simon Grant/research support from: Else Kröner-Memorial Scholarship, Novartis, Consultant of: Novartis, Lilly, Caroline Pecherstorfer: None declared, Hanna Ellmann: None declared, Camille Figueiredo: None declared, Matthias Englbrecht: None declared, Axel Hueber Grant/research support from: Novartis, Lilly, Pfizer, EIT Health, EU-IMI, DFG, Universität Erlangen (EFI), Consultant of: Abbvie, BMS, Celgene, Gilead, GSK, Lilly, Novartis, Speakers bureau: GSK, Lilly, Novartis, Arnd Kleyer Consultant of: Lilly, Gilead, Novartis,Abbvie, Speakers bureau: Novartis, Lilly, Jürgen Rech Consultant of: BMS, Celgene, Novartis, Roche, Chugai, Speakers bureau: AbbVie, Biogen, BMS, Celgene, MSD, Novartis, Roche, Chugai, Pfizer, Lilly, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB</jats:p></jats:sec>